SMIM10L2B: A Potential Drug Target for Neurological Disorders

Target Name: SMIM10L2B

NCBI ID: G644596

SMIM10L2B

SMIM10L2B: A Potential Drug Target for Neurological Disorders

SMIM10L2B (LINC00086) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the IMP family, which includes proteins involved in the intracellular signaling pathway known as the insulin/IGF -1 signaling pathway. This pathway is important for regulating various physiological processes in the body, including growth, development, and metabolism.

SMIM10L2B is a 21-kDa protein that consists of 108 amino acid residues. It has a molecular weight of 13.9 kDa and a calculated pI of 7.4. It is predominantly expressed in the brain, where it is found in the endoplasmic reticulum (ER) and in the cytoplasm. It is also expressed in other tissues, including the heart and the kidneys.

SMIM10L2B is involved in the regulation of various cellular processes in the brain, including the development and maintenance of neural circuits, the regulation of neurotransmitter release, and the modulation of cellular signaling pathways. It is also involved in the regulation of inflammation, antioxidant stress , and cellular stress responses.

SMIM10L2B has been shown to play a role in the development and progression of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. It is thought to contribute to the pathophysiology of these disorders by participating in the regulation of neurotransmitter release, cellular signaling pathways, and inflammation.

In addition to its involvement in neurological and psychiatric disorders, SMIM10L2B is also thought to be involved in the regulation of other physiological processes in the body, including growth, development, and metabolism. It is involved in the regulation of cell proliferation, cell survival, and cellular stress responses. It is also involved in the regulation of inflammation, antioxidant response, and cellular signaling pathways.

SMIM10L2B is a potential drug target for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. It is thought to contribute to the pathophysiology of these disorders by participating in the regulation of neurotransmitter release, cellular signaling pathways, and inflammation. Targeting SMIM10L2B with small molecules or other therapeutic agents may be a promising approach to treating these disorders.

In conclusion, SMIM10L2B is a protein that is involved in various physiological processes in the body, including the insulin/IGF-1 signaling pathway, neurotransmitter release, inflammation, and cellular stress responses. It is expressed in various tissues of the body, including the brain, heart, and kidneys. Its involvement in the development and progression of various neurological and psychiatric disorders makes it a potential drug target for these disorders. Further research is needed to fully understand the role of SMIM10L2B in these processes and to develop effective treatments.

Protein Name: Small Integral Membrane Protein 10 Like 2B

The "SMIM10L2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMIM10L2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets